PriceTargets.com logo

Medexus Pharmaceuticals - MDP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$3.18
  • Forecasted Upside: -59.03%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$7.75 As of 06/17/2021 12:59 AM ET
▼ -0.4 (-4.91%)

This chart shows the closing price for MDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medexus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDP

Analyst Price Target is C$3.18
▼ -59.03% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Medexus Pharmaceuticals in the last 3 months. The average price target is C$3.18, with a high forecast of C$4.00 and a low forecast of C$2.35. The average price target represents a -59.03% upside from the last price of C$7.75.

This chart shows the closing price for MDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Medexus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/22/2024Stifel NicolausLower TargetC$2.85 ➝ C$2.35
10/17/2023Raymond JamesSet TargetOutperformC$4.00
8/14/2023Stifel NicolausBoost TargetC$1.80 ➝ C$3.50
6/23/2023Stifel NicolausUpgradeHold ➝ Speculative Buy
3/10/2023Raymond JamesBoost TargetOutperformC$3.50 ➝ C$4.00
2/10/2023Raymond JamesLower TargetOutperformC$4.00 ➝ C$3.50
2/10/2023Canaccord Genuity GroupBoost TargetC$3.00 ➝ C$4.00
2/10/2023Stifel NicolausDowngradeBuy ➝ Hold
11/10/2022Raymond JamesUpgradeMarket Perform ➝ OutperformC$2.00 ➝ C$4.00
10/7/2022Canaccord Genuity GroupBoost TargetC$2.75 ➝ C$3.00
9/22/2022Canaccord Genuity GroupLower TargetC$3.50 ➝ C$2.75
9/20/2022Raymond JamesDowngradeOutperform ➝ Market PerformC$4.50 ➝ C$2.00
8/10/2022Stifel NicolausLower TargetC$14.25 ➝ C$11.00
7/26/2022Raymond JamesSet TargetOutperformC$4.50
3/2/2022Raymond JamesBoost TargetOutperformC$5.50 ➝ C$5.75
2/22/2022Raymond JamesSet TargetOutperformC$5.50
2/23/2021Bloom BurtonUpgradeAccumulate ➝ Buy
7/3/2019Bloom BurtonReiterated RatingAccumulate
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Medexus Pharmaceuticals logo
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
Read More

Today's Range

Now: C$7.75
Low: C$7.70
High: C$8.14

50 Day Range

MA: C$7.75
Low: C$7.75
High: C$7.75

52 Week Range

Now: C$7.75
Low: C$2.80
High: C$9.75

Volume

40,981 shs

Average Volume

68,619 shs

Market Capitalization

C$148.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medexus Pharmaceuticals?

The following Wall Street research analysts have issued reports on Medexus Pharmaceuticals in the last year: Raymond James, and Stifel Nicolaus.
View the latest analyst ratings for MDP.

What is the current price target for Medexus Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Medexus Pharmaceuticals in the last year. Their average twelve-month price target is C$3.18, suggesting a possible downside of 59.0%. Raymond James has the highest price target set, predicting MDP will reach C$4.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of C$2.35 for Medexus Pharmaceuticals in the next year.
View the latest price targets for MDP.

What is the current consensus analyst rating for Medexus Pharmaceuticals?

Medexus Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDP will outperform the market and that investors should add to their positions of Medexus Pharmaceuticals.
View the latest ratings for MDP.

What other companies compete with Medexus Pharmaceuticals?

Other companies that are similar to Medexus Pharmaceuticals include HLS Therapeutics, Cardiol Therapeutics, Leaf Mobile, BioSyent and Cipher Pharmaceuticals. Learn More about companies similar to Medexus Pharmaceuticals.

How do I contact Medexus Pharmaceuticals' investor relations team?

The company's listed phone number is 514-762-2626. The official website for Medexus Pharmaceuticals is www.medexus.com. Learn More about contacing Medexus Pharmaceuticals investor relations.